Molecular effects of curcumin on the experimental autoimmune ‎encephalomyelitis

Document Type : Original Article

Authors

1 Department of Biology, Faculty of Sciences, Urmia University, Urmia, Iran

2 Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). Previous studies have shown that myelin degradation during MS and EAE resulted in reduced expression of some of the proteins, e.g., the MBP (myelin basic protein), and increased expression of genes such as iNOS (Inducible nitric oxide synthase) and NOGO-A in the affected patients. In the present study, EAE was induced by immunizing Wistar rats (n=12) with homogenized spinal cord of guinea pig and Freund's complete adjuvant. Curcumin is an active ingredient in turmeric with anti-inflammatory properties, which has been studied in this article. In this study, the effect of curcumin administration on the change of the expression of MBP, NOGO-A, and iNOS genes was evaluated using the RT-PCR (Reverse transcription-polymerase chain reaction) technique. The obtained results indicated it could be concluded that curcumin was able to improve EAE by increasing the amount of MBP gene expression and reducing the intensity of NOGO-A expression.

Keywords


  1. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 2010; 1802(1):66-79.
  2. Ascherio A, Munger KL. Epidemiology of multiple sclerosis: From risk factors to prevention- An update. Semin Neurol 2016; 36(2): 103-114.
  3. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011; 234(1-2):7-18.
  4. Goldenberg MM. Multiple sclerosis review. Pharmacol. Ther 2012; 37(3):175-184.
  5. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012; 142(1):2-8.
  6. Kuerten S, Lehmann PV. The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis? J Interferon Cytokine Res 2011; 31(12):907-916.
  7. Lees JR, Iwakura Y, Russell JH. Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines. J Immunol 2008;180(12):8066-8072.
  8. Palma M, Piñeiro Z, Barroso CG. Stability of phenolic compounds during extraction with superheated solvents. J Chromatogr A 2001;921(2):169-174.
  9. Verghese J. Isolation of curcumin from Curcuma longa L. rhizome. Flavour Fragr J 1993;8(6):315-319.
  10. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014;46(1):2-18
  11. Kiuchi F, Goto Y, Sugimoto N, et al. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull (Tokyo) 1993;41(9):1640-1643.
  12. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer lett 2008;269(2):199-225.
  13. Martín-Cordero C, López-Lázaro M, Gálvez M, et al. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 2003; 18(6):505-509.
  14. Tilak JC, Banerjee M, Mohan H, et al. Antioxidant availability of turmeric in relation to its medicinal and culinary uses. Phytother Res 2004; 18(10):798-804.
  15. Huang HC, Jan TR, Yeh SF. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 1992; 221(2-3):381-384.
  16. Kohli K, Ali J, Ansari M, et al. Curcumin: A natural anti-inflammatory agent. Indian J Pharmacol 2005; 37 (3):141-147.
  17. Park SY, Kim DSHL. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J Nat Prod 2002; 65(9):1227-1231.
  18. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008; 58(4):625-631.
  19. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008; 114(2):127-149.
  20. Priyadarsini KI, Maity DK, Naik GH, et al. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic Biol Med 2003; 35(5):475-484.
  21. Zirak Marangalu H, Khezri S, Abtahi M. Improvement in the function of rat peripheral blood monocytes following oral administration of curcumin. JSSU 2017; 25(3):171-182.
  22. Bright JJ. Curcumin and autoimmune disease. In: Aggarwal BB, Surh YJ, ‎Shishoida S (Eds). The molecular targets and therapeutic uses of curcumin in health ‎and disease Boston, USA: Springer 2007; 425-451.‎
  23. Rozenblum GT, Kaufman T, Vitullo AD. Myelin basic protein and a multiple sclerosis-related MBP-peptide bind to oligonucleotides. Mol Ther Nucleic Acids 2014; 3(9): e192. doi: 10.1038/mtna.2014.43.
  24. Kröncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 1998;113(2):147-156.
  25. Brittis PA, Flanagan JG. Nogo domains and a Nogo receptor: implications for axon regeneration. Neuron 2001;30(1):11-14.
  26. Soetikno V, Sari FR, Veeraveedu PT, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab 2011; 8(1):35. doi:10.1186/1743-7075-8-35.
  27. Chen GQ, Chen YY, Wang XS, et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res 2010; 1309:116-125.
  28. Khezri S, Abtahi Froushani SM, Shahmoradi M. Nicotine augments the beneficial effects of mesenchymal stem cell-based therapy in rat model of multiple sclerosis. Immunol Invest 2018;47(2):113-124.
  29. Skundric DS, Zakarian V, Dai R, et al. Distinct immune regulation of the response to H-2b restricted epitope of MOG causes relapsing–remitting EAE in H-2b/s mice. J Neuroimmunol 2003;136(1-2):34-45.
  30. Barres BA. New roles for glia. J Neurosci. 1991; 11(12):3685-3694.
  31. Sharman MJ, Gyengesi E, Liang H, et al. Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and α-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective? Neurobiol Dis 2019; 124:505-519.
  32. Pluta R, Ułamek-Kozioł M, Czuczwar S. Neuro-protective and neurological/cognitive enhancement effects of curcumin after brain ischemia injury with Alzheimer’s disease phenotype. Int J Mol Sci 2018;19(12):4002. doi: 10.3390/ijms19124002.
  33. Abdel-Diam MM, Samak DH, El-Sayed YS, et al. Curcumin and quercetin synergistically attenuate sub-acute diazinon-induced inflammation and oxidative neurohepatic damage, and acetylcholinesterase inhibition in albino rats. Environ Sci Pollut Res Int 2019;26(4): 3659-3665.
  34. Seyedzadeh MH, Safari Z, Zare A, et al. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int Immunopharmacol 2014;22(1):230-235.
  35. Xie L, Li X-K, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009;9(5):575-581.
  36. Fahey AJ, Adrian Robins R, Constantinescu CS. Curcumin modulation of IFN‐β and IL‐12 signalling and cytokine induction in human T cells. J Cellular Mol Med 2007; 11(5):1129-1137.
  37. Feng J, Tao T, Yan W, et al. Curcumin inhibits mitochondrial injury and apoptosis from the early stage in EAE mice. Oxid Med Cell Longev 2014: 728751. doi: 10.1155/2014/728751.
  38. Chearwae W, Bright JJ. 15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in auto-immune T lymphocyte. J Clin Immunol 2008; 28(5): 558-570.
  39. Bos S, Berge T, Celius E, et al. From genetic associations to functional studies in multiple sclerosis. Eur J Neurol 2016;23(5):847-853.
  40. Tomassini V, Pozzilli C. Sex hormones, brain damage and clinical course of Multiple Sclerosis. J NeurolSci. 2009; 286(1-2):35-39.
  41. Franklin RJM, Ffrench-Contant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9(11): 839-855.
  42. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87(1):315-424.
  43. D'Aversa TG, Eugenin EA, Lopez L, et al. Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis. Neuropathol Appl Neurobiol 2013;39(3):270-283.
  44. He Z, Koprivica V. The Nogo signaling pathway for regeneration block. Annu Rev Neurosci 2004; 27:341-368.
  45. Liu JS, Zhao ML, Brosnan CF, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001;158 (6):2057-2066.